- Home
- NUAI vs IKT Comparison
NUAI vs IKT Comparison
Compare NUAI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUAI | IKT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 201.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NUAI | IKT |
|---|---|---|
| Price | $4.61 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 7.5M | 673.2K |
| Earning Date | 03-31-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $843,029.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.89 | N/A |
| 52 Week Low | $0.32 | $1.33 |
| 52 Week High | $9.45 | $3.32 |
Technical Indicators
Market Signals| Indicator | NUAI | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 48.49 |
| Support Level | $4.78 | $1.57 |
| Resistance Level | $5.39 | $1.72 |
| Average True Range (ATR) | 1.00 | 0.10 |
| MACD | -0.30 | 0.01 |
| Stochastic Oscillator | 0.26 | 53.70 |
Price Performance
Historical ComparisonAbout NUAI New Era Energy & Digital Inc.
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.